Video
Dr. Lencioni on Assessing Response to HCC Therapy
Author(s):
Riccardo Lencioni, MD, professor in the department of radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.
Riccardo Lencioni, MD, professor in the Department of Radiology at the University of Pisa School of Medicine in Pisa, Italy, discusses how response to hepatocellular carcinoma (HCC) treatment can be best assessed in patients.
For patients who receive locoregional therapies, there is a general consensus that using modified Response Evaluation Criteria in Solid Tumors (mRECIST) provides useful and reliable predictors of patient survival. However, there are emerging data that mRECIST criteria may also be an independent predictor of survival for patients with advanced HCC who are receiving systemic therapies.
Applying these criteria in assessing patient response to treatment will be increasingly important as the treatment landscape for HCC expands with the addition of new agents. Understanding which patients benefit most from particular therapies will be of particular value in tailoring patient care.
View more from the 2018 International Liver Cancer Association Annual Conference
Brought to you in part by Eisai
